BONE MARROW CONDITIONING/CD66
The indications for bone marrow transplantation are increasing from haematological malignancies to solid tumours and autoimmune conditions.
Traditional conditioning regimens are associated with morbidity and mortality from chemotherapy, limiting their use particularly in paediatric and rare diseases.
CD66 is a receptor expressed on granulocytes and a potential target for novel conditioning radiopharmaceuticals and has been granted orphan drug designation (ODD) status in Europe for bone marrow conditioning for hematopoietic stem cell transplantation (HSCT), a broad clinical indication.
For more information on Telix’s active clinical trials in rare disease and bone marrow conditioning please see trial descriptions below, clickable through to clinical trial database where registered.
